25.1K
Downloads
592
Episodes
Podcasts for antibody-based pharmaceuticals including Therapeutic antibody/Antibody-drug conjugates/vaccine/CAR-T/Immunotherapy. Creative-Biolabs, the provider, is an outsourced research organization for antibody-drug development.
Episodes
Dec 28, 2022
Dec 28, 2022
16 min
This episode focuses on obstacles and corresponding strategies in allogeneic hematopoietic cell transplantation, and the progress in generating cytomegalovirus-specific T cells.
Dec 21, 2022
Dec 21, 2022
17 min
Creative Biolabs has archived professional academic reports and the latest scientific progress of oncolytic virotherapy, by making it into a podcast column.
Dec 21, 2022
Dec 21, 2022
12 min
Creative Biolabs has archived professional academic reports and the latest scientific progress of oncolytic virotherapy, by making it into a podcast column.
Dec 21, 2022
Dec 21, 2022
9 min
Creative Biolabs has archived professional academic reports and the latest scientific progress of oncolytic virotherapy, by making it into a podcast column.
Dec 21, 2022
Dec 21, 2022
13 min
Creative Biolabs has archived professional academic reports and the latest scientific progress of oncolytic virotherapy, by making it into a podcast column.
Dec 21, 2022
Dec 21, 2022
11 min
Creative Biolabs has archived professional academic reports and the latest scientific progress of oncolytic virotherapy, by making it into a podcast column.
Dec 21, 2022
Dec 21, 2022
9 min
Creative Biolabs has archived professional academic reports and the latest scientific progress of oncolytic virotherapy, by making it into a podcast column.
Dec 21, 2022
Dec 21, 2022
9 min
Creative Biolabs has archived professional academic reports and the latest scientific progress of oncolytic virotherapy, by making it into a podcast column.
Dec 21, 2022
Dec 21, 2022
10 min
Creative Biolabs has archived professional academic reports and the latest scientific progress of oncolytic virotherapy, by making it into a podcast column.
Dec 21, 2022
Dec 21, 2022
13 min
This episode focuses on various aspects of TCR-engineered T-cell therapy, such as risks, clinical trials, and comparison between TCR-engineered T cells and CAR-T cells.